Fig. 4: Evolution of HER2 expression according to breast cancer subtype. | npj Breast Cancer

Fig. 4: Evolution of HER2 expression according to breast cancer subtype.

From: HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment

Fig. 4

These Sankey diagramas show the evolution of HER2 expression from baseline biopsy to residual disease after neoadjuvant chemotherapy in patients failing to achieve pCR in the HER2-negative cohort according to breast cancer phenotype. a Evolution of HER2 expression in HR+/HER2+subtype; b Evolution of HER2 expression in TN subtype. HR+ hormone-receptor positive, TN triple-negative.

Back to article page